Targeted Protein Degradation– tag –
-
FDA Grants Accelerated Approval to BMS’s Zenbexus for Multiple Myeloma in Combination with Daratumumab
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's (BMS) Zenbexus (iberdomide), a novel CELMoD (cereblon E3 ligase modulator), for the treatment of multiple myelom... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
C4 Therapeutics Grants Stock Options to New Employees Under Nasdaq Rule, Bolstering TPD Talent Acquisition
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) announced it has granted stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4). This inducement grant is a critical component of the company's strategy to adv... -
C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This str... -
FDA Grants Accelerated Approval to BMS’s CELMoD Zenbexus in Quadruple Therapy for Relapsed/Refractory Multiple Myeloma
Drugs.com, FDA.gov USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexametha... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
Kymera Therapeutics’ Oral STAT6 Degrader KT-621 Shows Positive Phase 1b Atopic Dermatitis Data, Potential Injectable Alternative
TradingView Global Overview Kymera Therapeutics' lead candidate, KT-621 (an oral STAT6 degrader leveraging targeted protein degradation), demonstrated positive Phase 1b data in atopic dermatitis. Presented at the American Academy of Derm... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra...
